KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT05027867. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multicenter, Phase 2 Study of the Safety and Efficacy of KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer (SCLC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with relapsed or refractory small cell lung cancer. This study will be conducted in 2 parts. Part 1 will evaluate two treatment arms, each with a different KRT-232 dose. Part 2 will continue the evaluation of the selected treatment arms from Part 1.
Study identification
- NCT ID
- NCT05027867
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 3 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 6, 2021 (Actual)
- Primary completion
- Aug 26, 2022 (Actual)
- Completion
- Aug 26, 2022 (Actual)
- Last update posted
- Aug 16, 2023
2021 – 2022
United States locations
- U.S. sites
- 9
- U.S. states
- 5
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Florida Cancer Specialists - 3840 Broadway | Fort Myers | Florida | 33901 | — |
| Florida Cancer Specialists - 560 Jackson St, Suite 220 | St. Petersburg | Florida | 33705 | — |
| Florida Cancer Specialists | West Palm Beach | Florida | 33401 | — |
| Northwest Georgia Oncology Centers | Marietta | Georgia | 30060 | — |
| Hematology Oncology Clinic | Baton Rouge | Louisiana | 70809 | — |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 | — |
| Mark H Zangmeister Center - 3100 Plaza Properties Boulevard | Columbus | Ohio | 43213 | — |
| SCRI Tennessee Oncology Chattanooga | Chattanooga | Tennessee | 37404 | — |
| SCRI Tennessee Oncology Nashville | Nashville | Tennessee | 37205 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05027867, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 16, 2023 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05027867 live on ClinicalTrials.gov.